The biggest newcomers immediately land on the list by way of initial public offerings or spin-offs of major subsidiaries of their former parent companies, who are also on our list.
Later this year, Merck expects to refile Arcoxia in the U.S. and either spin off or do an initial public offering for its pharmacy-benefits manager unit, Medco.